The disruption caused by the COVID-19 pandemic has been a watershed moment forcing the transformation of legacy business models across many industries.
The pharmaceutical industry, too, has been profoundly affected by the pandemic fallout, as health systems are reeling from severe financial pressures and continue to struggle under operational strains, while expectations of patients and healthcare professionals are being reset. The pandemic has reconfigured many care pathways, often away from the traditional clinical setting; it has forced reduced reliance on the traditional sales forces and detailing model, elevating the role of medical and remote channels; it has shown that in some cases the research and development process can happen at unprecedented speed; and it has created a backlog of urgent patient care.
但是，从RWE（大规模）对价值的系统捕获需要高级计划，跨职能执行，与付款人和监管机构等外部利益相关者的早期互动，连接数据，技术和操作，最重要的是，为灵活的选择做出了正确的选择访问迅速发展的RWE功能并建立高效且可持续的RWE资金模型。
Read our latest whitepaper to learn more
